Therefore, drug discovery processes should be directed in the future to develop new drugs that are able to interfere with early CNS inflammation and, at the same time, rescue neurotrophin signaling (e.g., BDNF, NGF, TGF-β1) in the AD brain. Here, TGFB1 is linked to Alzheimer disease.